All News
Predictors and Outcomes in Systemic Sclerosis
EurekAlert!
The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will fulfil the 2013 ACR/EULAR SSc criteria within 5 years.
Read Article
EULAR 2025 – Day 2 Report
Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today.
Read Article
Secukinumab Use in Refractory Giant Cell Arteritis
In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab.
Migrant health literacy challenges - Individual interviews with participants with rheumatic diseases (interpreters used)
multiple aspects -
Individual, Providers and system level
Navigating health care systems
#EULAR2025 @RheumNow https://t.co/cWQ6jP8RZe
Bella Mehta bella_mehta ( View Tweet)
Great talk by @Lupusreference on Relapsing Polychondritis and a highlight of #EULAR2025. Do not forget about the articular presentations of relapsing polychondritis @RheumNow https://t.co/1xZY7VkX1z
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
"H Syndrome" review of 23 French pts. Autoinflammatory dz due to variants of SLC29A3 gene. Multisystem histiocytic lymphoproliferative disorder of young adults- skin 2/3, sensorineural hearing loss, fever w/ endo & autoimmune dz. Best responses w IL6 inhib. #EULAR2025 Abst https://t.co/F7NGI4TkJS
Dr. John Cush RheumNow ( View Tweet)
#EULAR2025 Abstr#OP0319 Multicentre study in Canada showed no difference in longterm Lung Transplant outcomes among IIM-ILD, SSc-ILD & IPF. Some differences: IIM-ILD was progressive pre-transplant with prolonged hospitalisation post-surgery. For us to be aware @RheumNow https://t.co/eFdY4XGtlj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
SLE Preview: advances to achieve deep B-cell depletion
The race is on for the first chimeric antigen receptor (CAR)-based therapy to be approved for the treatment of systemic lupus erythematosus (SLE). Its main principle is to induce deep B-cell depletion, with the hope to reset https://t.co/OzQ05YFZfb
Dr. John Cush RheumNow ( View Tweet)
Worth mentioning: the type of monoclonal protein is important for diagnosis. Different diseases with different therapies #EULAR2025 @RheumNow l https://t.co/5bbQnHV6CI
David Liew drdavidliew ( View Tweet)
Age of onset is really important when thinking about #MAS
Primary HLH more frequent in pediatric population. But can continue to adulthood.
#EULAR2025 @RheumNow https://t.co/J7xmTiQiwr
Bella Mehta bella_mehta ( View Tweet)
MAS can be triggered by infections in VEXAS syndrome. The threshold is reached leading to a hyperinflammatory state
Georgin-Lavialle S @rheumnow #EULAR2025 https://t.co/NKLL75rOgP
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
3 Fs of diagnosis of #HLH
-Fever
-Ferritin
-Falling blood count
Raising awareness is the key! Especially in rare diseases like this where the morbidity and mortality is super high!
Collaboration between specialists help
HLH networks will be helpful like this
@RheumNow #EULAR2025 https://t.co/HWbvIma3yx
Bella Mehta bella_mehta ( View Tweet)
Treatment strategies for steroid free management of #relapsingpolychondritis
56 patients from a single center
#POS0149 #EULAR2025 @RheumNow https://t.co/d4I56opS02
Bella Mehta bella_mehta ( View Tweet)
#MITIGATE subgroup analysis: Inebilizumab reduced flares & boosted remission across all #IgG4-RD subgroups. HR for flare vs PBO: 0.12-0.16 across sex/race. Similar results for all subgroups in achieving flare-free, treatment-free complete remission.
@RheumNow #EULAR2025 #OP0189
Mrinalini Dey DrMiniDey ( View Tweet)
RA-related premature mortality highest in American Indians--> 3.6x odds of death in <65 vs White peers, w/ no improvement over 22 yrs. COVID widened the gap. Need to address structural & social drivers of early death in RA, & wider health disparities.
@RheumNow #EULAR2025 #OP0197
Mrinalini Dey DrMiniDey ( View Tweet)
Got paraproteinemia? Here’s what to think about, from a rheumatology point of view. @RheumNow #EULAR2025 https://t.co/eu7Mi5yeum
David Liew drdavidliew ( View Tweet)
In >228k CTD patients across France, ILD increased mortality risk across all CTDs. Proportion of incident CTD with ILD highest in IIM (37%). Up to 34% of CTD-ILD pts had progressive pulm fibrosis. Supports earlier ILD screening & vigilance in CTDs.
@RheumNow #EULAR2025 #OP0033 https://t.co/KkF9xFY4Cn
Mrinalini Dey DrMiniDey ( View Tweet)
Uncontrolled pilot trial of frequency specific microcurrent treatment given to 17 pts w/ Raynaud’s & systemic sclerosis. Microcurrent Rx given for 45-60 min over 1-2d; w/ average improvement of 40% in hand function & Raynauds improvement ~18% p .016)- RCT needed!! https://t.co/4OUeODuj8Q
Dr. John Cush RheumNow ( View Tweet)
Global incidence of alopecia areata increased betw 1990 - 2021; from 20.43 million (19.77-21.09 million) in 1990 to 30.89 million in 2021 ( range of 29.95-31.82 million) - highest in USA 550/100,000. High in N.America, S.America, Southeast Asia, Australia. Lowestin Africa, Middle https://t.co/GxrZPY5NBc
Dr. John Cush RheumNow ( View Tweet)
Blau syndrome -a rare autoinflammatory Dz w/ triad of granulomatous dermatitis, arthritis, & uveitis (may cause blindness); from a NOD2 gain-of-function mutations. Onset age 2-4 yrs. Early biologics (esp TNFi) may prevent joint complications; but metanalysis shows no preferred https://t.co/wYTNv50tqM
Dr. John Cush RheumNow ( View Tweet)
